Glycopeptide-resistant Enterococcus faecium infections in paediatric liver transplant recipients:: safety and clinical efficacy of quinupristin/dalfopristin

被引：15

作者：

Verma, A ^{[1
]}

Dhawan, A

Philpott-Howard, J

Rela, M

Heaton, N

Vergani, GM

Wade, J

机构：

[1] Kings Coll London Hosp, Dulwich Publ Hlth Lab, London SE5 9RS, England

[2] Kings Coll London Hosp, Paediat Liver Serv, London SE5 9RS, England

来源：

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2001年 / 47卷 / 01期

关键词：

D O I：

10.1093/jac/47.1.105

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

We describe our experience of quinupristin/dalfopristin for glycopeptide-resistant Enterococcus faecium (GREF) infections in 19 paediatric liver transplant recipients. The median patient age was 2 years and all were receiving immunosuppressive regimens. Quinupristin/dalfopristin was well tolerated and complete resolution of infection was seen in 74% of patients. Side-effects included reversible elevation of serum alkaline phosphatase, skin rash, itching, diarrhoea and vomiting, but therapy was not withdrawn from any patient. Quinupristin/dalfopristin appears safe and efficacious in critically ill immunocompromised children with renal or hepatic Impairment.

引用

页码：105 / 108

页数：4

共 10 条

[1]

Barrow GI., 1993, COWAN STEELS MANUAL, V3th

[2] INVITRO ACTIVITY OF RP59500, AN INJECTABLE STREPTOGRAMIN ANTIBIOTIC, AGAINST VANCOMYCIN-RESISTANT GRAM-POSITIVE ORGANISMS [J].

COLLINS, LA ;

MALANOSKI, GJ ;

ELIOPOULOS, GM ;

WENNERSTEIN, CB ;

FERRARO, MJ ;

MOELLERING, RC .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (03) :598-601

[3] SEPSIS TERMINOLOGY IN PEDIATRICS [J].

HAYDEN, WR .

JOURNAL OF PEDIATRICS, 1994, 124 (04) :657-658

[4] Management of infections due to resistant enterococci: a review of therapeutic options [J].

Landman, D ;

Quale, JM .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 40 (02) :161-170

[5] Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort [J].

Linden, PK ;

Pasculle, AW ;

McDevitt, D ;

Kramer, DJ .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1997, 39 :145-151

[6] Differences in outcomes for patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E-faecium [J].

Linden, PK ;

Pasculle, AW ;

Manez, R ;

Kramer, DJ ;

Fung, JJ ;

Pinna, AD ;

Kusne, S .

CLINICAL INFECTIOUS DISEASES, 1996, 22 (04) :663-670

[7] The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium [J].

Moellering, RC ;

Linden, PK ;

Reinhardt, J ;

Blumberg, EA ;

Bompart, F ;

Talbot, GH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (02) :251-261

[8] Drug therapy: Vancomycin-resistant enterococcal infections. [J].

Murray, BE .

NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (10) :710-721

[9]

National Committee for Clinical Laboratory Standards, 1997, METH DIL ANT SUSC TE

[10] THE NEED FOR BIOLOGICAL ASSESSMENT OF WATER-QUALITY - AUSTRALIAN PERSPECTIVE [J].

NORRIS, RH ;

NORRIS, KR .

AUSTRALIAN JOURNAL OF ECOLOGY, 1995, 20 (01) :1-6

← 1 →